AOD-9604 vs Tirzepatide
Both AOD-9604 and Tirzepatide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →Side-by-Side
| Attribute | AOD-9604 | Tirzepatide |
|---|---|---|
| Evidence Grade | C+ | A+ |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | FDA-approved for weight management and type 2 diabetes |
| Typical Dose | 250–500 mcg daily (subcutaneous) | 2.5–15 mg weekly (subcutaneous injection) |
| Clinics Indexed | 134 | 1,850 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.